1. Home
  2. CRNX vs MNTSW Comparison

CRNX vs MNTSW Comparison

Compare CRNX & MNTSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$33.73

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Momentus Inc.

MNTSW

Momentus Inc.

N/A

Current Price

$0.02

Market Cap

0.0

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CRNX
MNTSW
Founded
2008
N/A
Country
United States
United States
Employees
N/A
123
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
N/A
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
CRNX
MNTSW
Price
$33.73
$0.02
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$74.78
N/A
AVG Volume (30 Days)
1.0M
106.9K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$722.66
N/A
Revenue Next Year
$183.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.10
$0.01
52 Week High
$57.99
$0.10

Technical Indicators

Market Signals
Indicator
CRNX
MNTSW
Relative Strength Index (RSI) 29.20 50.78
Support Level $33.23 $0.01
Resistance Level $37.23 $0.03
Average True Range (ATR) 1.62 0.00
MACD 0.13 0.00
Stochastic Oscillator 8.33 39.42

Price Performance

Historical Comparison
CRNX
MNTSW

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About MNTSW Momentus Inc.

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

Share on Social Networks: